

Michele Prisciandaro

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/285273/publications.pdf>

Version: 2024-02-01

45
papers

984
citations

567281

15
h-index

477307

29
g-index

45
all docs

45
docs citations

45
times ranked

2155
citing authors

#	ARTICLE	IF	CITATIONS
1	Variant allele frequency in baseline circulating tumour DNA to measure tumour burden and to stratify outcomes in patients with RAS wild-type metastatic colorectal cancer: a translational objective of the Valentino study. <i>British Journal of Cancer</i> , 2022, 126, 449-455.	6.4	15
2	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with <i>RAS</i> Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study. <i>Oncologist</i> , 2022, 27, e29-e36.	3.7	3
3	Biomarker Landscape in Neuroendocrine Tumors With High-Grade Features: Current Knowledge and Future Perspective. <i>Frontiers in Oncology</i> , 2022, 12, 780716.	2.8	4
4	Early modulation of Angiopoietin-2 plasma levels predicts benefit from regorafenib in patients with metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2022, 165, 116-124.	2.8	6
5	Early onset metastatic colorectal cancer in patients receiving panitumumab-based upfront strategy: Overall and sex-specific outcomes in the Valentino trial. <i>International Journal of Cancer</i> , 2022, 151, 1760-1769.	5.1	6
6	Validation of the Colon Life nomogram in patients with refractory metastatic colorectal cancer enrolled in the RECURSE trial. <i>Tumori</i> , 2021, 107, 353-359.	1.1	5
7	Impact of early tumor shrinkage and depth of response on the outcomes of panitumumab-based maintenance in patients with RAS wild-type metastatic colorectal cancer. <i>European Journal of Cancer</i> , 2021, 144, 31-40.	2.8	12
8	Systemic doxycycline for pre-emptive treatment of anti-EGFR-related skin toxicity in patients with metastatic colorectal cancer receiving first-line panitumumab-based therapy: a post hoc analysis of the Valentino study. <i>Supportive Care in Cancer</i> , 2021, 29, 3971-3980.	2.2	4
9	Optimized EGFR Blockade Strategies in <i>EGFR</i> Addicted Gastroesophageal Adenocarcinomas. <i>Clinical Cancer Research</i> , 2021, 27, 3126-3140.	7.0	11
10	The Added Value of Baseline Circulating Tumor DNA Profiling in Patients with Molecularly Hyperselected, Left-sided Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 2505-2514.	7.0	14
11	Personalized therapeutic strategies in HER2-driven gastric cancer. <i>Gastric Cancer</i> , 2021, 24, 897-912.	5.3	6
12	Prognostic impact of early tumor shrinkage and depth of response in patients with microsatellite instability-high metastatic colorectal cancer receiving immune checkpoint inhibitors. , 2021, 9, e002501.		18
13	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021, 22, 161-169.	2.6	17
14	Tremellmumab and Durvalumab Combination for the Non-Operative Management (NOM) of Microsatellite Instability (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-Arm, Multi-Cohort, Phase II INFINITY Study. <i>Cancers</i> , 2021, 13, 2839.	3.7	31
15	TP53 Mutation Analysis in Gastric Cancer and Clinical Outcomes of Patients with Metastatic Disease Treated with Ramucirumab/Paclitaxel or Standard Chemotherapy. <i>Cancers</i> , 2020, 12, 2049.	3.7	11
16	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2468.	2.4	11
17	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092727.	3.2	8
18	Antitumor activity and efficacy of shorter versus longer duration of anthracycline-taxane neoadjuvant chemotherapy in stage II-III HER2-negative breast cancer: a 10-year, retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097008.	3.2	2

#	ARTICLE	IF	CITATIONS
19	Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability-High End-Stage Cancers and Poor Performance Status Related to High Disease Burden. <i>Oncologist</i> , 2020, 25, 803-809.	3.7	26
20	Glycolytic competence in gastric adenocarcinomas negatively impacts survival outcomes of patients treated with salvage paclitaxel-ramucirumab. <i>Gastric Cancer</i> , 2020, 23, 1064-1074.	5.3	5
21	Prognostic impact of immune-microenvironment in colorectal liver metastases resected after triplets plus a biologic agent: A pooled analysis of five prospective trials. <i>European Journal of Cancer</i> , 2020, 135, 78-88.	2.8	10
22	Oral Capecitabine-Vinorelbine Is Associated with Longer Overall Survival When Compared to Single-Agent Capecitabine in Patients with Hormone Receptor-Positive Advanced Breast Cancer. <i>Cancers</i> , 2020, 12, 617.	3.7	4
23	Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis. <i>Clinical Colorectal Cancer</i> , 2020, 19, 191-199.e6.	2.3	20
24	Clinical Behavior and Treatment Response of Epstein-Barr Virus-Positive Metastatic Gastric Cancer: Implications for the Development of Future Trials. <i>Oncologist</i> , 2020, 25, 780-786.	3.7	14
25	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	2.3	16
26	One size does not fit all for pancreatic cancers: A review on rare histologies and therapeutic approaches. <i>World Journal of Gastrointestinal Oncology</i> , 2020, 12, 833-849.	2.0	7
27	Developing a score system to predict therapeutic outcomes to anti-PD-1 immunotherapy in metastatic melanoma. <i>Tumori</i> , 2019, 105, 465-473.	1.1	4
28	Cabozantinib in Renal Cell Carcinoma With Brain Metastases: Safety and Efficacy in a Real-World Population. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 291-298.	1.9	30
29	Resistance mechanisms to anti-HER2 therapies in HER2-positive breast cancer: Current knowledge, new research directions and therapeutic perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 139, 53-66.	4.4	137
30	Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience. <i>Melanoma Research</i> , 2019, 29, 289-294.	1.2	5
31	The Landscape of Actionable Gene Fusions in Colorectal Cancer. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5319.	4.1	34
32	Safety and Efficacy of Cabozantinib for Metastatic Nonclear Renal Cell Carcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 42-45.	1.3	20
33	Perioperative Bevacizumab-based Triplet Chemotherapy in Patients With Potentially Resectable Colorectal Cancer Liver Metastases. <i>Clinical Colorectal Cancer</i> , 2019, 18, 34-43.e6.	2.3	7
34	Single-Agent Gemcitabine vs. Carboplatin-Gemcitabine in Advanced Breast Cancer: A Retrospective Comparison of Efficacy and Safety Profiles. <i>Clinical Breast Cancer</i> , 2019, 19, e306-e318.	2.4	16
35	Immune-related adverse events correlate with improved survival in patients undergoing anti-PD1 immunotherapy for metastatic melanoma. <i>Journal of Cancer Research and Clinical Oncology</i> , 2019, 145, 511-521.	2.5	153
36	Differential histopathologic parameters in colorectal cancer liver metastases resected after triplets plus bevacizumab or cetuximab: a pooled analysis of five prospective trials. <i>British Journal of Cancer</i> , 2018, 118, 955-965.	6.4	17

#	ARTICLE	IF	CITATIONS
37	RET fusions in a small subset of advanced colorectal cancers at risk of being neglected. <i>Annals of Oncology</i> , 2018, 29, 1394-1401.	1.2	72
38	Biomarkers of Primary Resistance to Trastuzumab in HER2-Positive Metastatic Gastric Cancer Patients: the AMNESIA Case-Control Study. <i>Clinical Cancer Research</i> , 2018, 24, 1082-1089.	7.0	76
39	Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. <i>Clinical Genitourinary Cancer</i> , 2018, 16, e945-e951.	1.9	30
40	Estimating Survival Probabilities of Advanced Gastric Cancer Patients in the Second-Line Setting: The Gastric Life Nomogram. <i>Oncology</i> , 2018, 95, 344-352.	1.9	11
41	The neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios predict efficacy of platinum-based chemotherapy in patients with metastatic triple negative breast cancer. <i>Scientific Reports</i> , 2018, 8, 8703.	3.3	43
42	Does Dose Modification Affect Efficacy of First-Line Pazopanib in Metastatic Renal Cell Carcinoma?. <i>Drugs in R and D</i> , 2017, 17, 461-467.	2.2	5
43	Personalized therapy in renal cell carcinoma: are the different tyrosine kinase inhibitors the same for any patient?. <i>Expert Review of Precision Medicine and Drug Development</i> , 2017, 2, 5-7.	0.7	3
44	Vinorelbine in BRAF V600E mutated metastatic colorectal cancer: a prospective multicentre phase II clinical study. <i>ESMO Open</i> , 2017, 2, e000241.	4.5	10
45	Nivolumab in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience. <i>Therapeutic Advances in Urology</i> , 2016, 8, 319-326.	2.0	25